Concurrently, The HPA was investigated to assess CHD1L protein expression in cancerous patients and the results indicated that CHD1L protein was overexpressed in most human cancers (Figure 1C) where it was overexpressed in about 100% of thyroid, colorectal, head and neck, stomach, carcinoid, pancreatic urothelial, prostate, testis, breast, ovarian and skin cancer patients. Here, CHD1L is linked to skin neoplasm.